Synonyms: Arcapta Neohaler® | Onbrez® | QAB-149 | QAB149
indacaterol is an approved drug (EMA (2009), FDA (2011))
Compound class:
Synthetic organic
Comment: Only the R-enantiomer, as the maleate salt (PubChem CID 9827599) is contained in the medicinal product.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: indacaterol |
|
No information available. |
Summary of Clinical Use |
Indacaterol is a very long-acting, rapid onset β2-adrenoceptor agonist [3] approved for the once-daily management of asthma and chronic obstructive pulmonary disease (COPD). A fixed-dose inhalation combination medicine containing incadaterol and glycopyrrolate (Utibron Neohaler) was approved by the US FDA in November 2015 for the treatment of COPD |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |